Key Insights

Highlights

Treatment Research

17 treatments under study, led by Liposomal Doxorubicin

Related Conditions

Often studied with 13 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

3Total
Phase 1 (1)
Phase 2 (2)

Trial Status

Unknown1
Recruiting1
Terminated1
Active Not Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT00092222Phase 2Active Not Recruiting

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

NCT01419561Phase 2Recruiting

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)

NCT05081141UnknownPrimary

HHV8 and Solid Organ Transplantation

NCT00287495Phase 1Terminated

BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma

Showing all 4 trials

Research Network

Common Treatments

  • Liposomal Doxorubicin2
  • Zidovudine2
  • Rituximab2
  • Interferonalpha1
  • Doxorubicin1

Active Sponsors

  • National Cancer Institute (NCI)3
  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico1

Top Investigators

Related Conditions

  • Kshv2
  • Kaposi Sarcoma1
  • Lung Transplant Complications1
  • Hiv1
  • Kshv Inflammatory Cytokine Syndrome Kics1

Activity Timeline